Core Viewpoint - WuXi AppTec has announced the sale of its clinical service subsidiaries, aiming to focus on its CRDMO business model and enhance global capabilities while reporting strong financial performance in the first three quarters of the year [1][2][9]. Group 1: Asset Sale Details - WuXi AppTec plans to sell 100% equity of its subsidiaries, Shanghai Kangde Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jishi Pharmaceutical Technology Co., Ltd., to Hillhouse Capital for a base price of 2.8 billion yuan [1]. - The two subsidiaries generated approximately 1.16 billion yuan in revenue and 90 million yuan in net profit for the first three quarters of 2025, accounting for 3.5% and 0.7% of WuXi AppTec's total revenue and net profit, respectively [2]. Group 2: Strategic Focus - The sale is part of WuXi AppTec's strategy to concentrate on its CRDMO business model, which includes drug discovery, laboratory testing, and process development, thereby providing financial support for global capacity expansion [2][7]. - The company has been optimizing its business structure over the past year, including the sale of its WuXi ATU business in the U.S. and U.K., which contributed 1.32 billion yuan in revenue for 2024 [3]. Group 3: Financial Performance - For the first three quarters of 2025, WuXi AppTec reported revenue of 32.857 billion yuan, a year-on-year increase of 18.61%, and a net profit of 12.076 billion yuan, up 84.84% [9]. - The chemical segment was the largest revenue contributor, generating 25.98 billion yuan, a 29.3% increase year-on-year [10]. - The U.S. market remains the primary revenue source, with 22.15 billion yuan in revenue, reflecting a 31.9% growth [11].